

1 **Erythrocyte n-6 polyunsaturated fatty acids, gut microbiota and incident type 2**

2 **diabetes: a prospective cohort study**

3 Zelei Miao^{1#}, Jie-sheng Lin^{2#}, Yingying Mao^{3#}, Geng-dong Chen², Fang-fang Zeng^{2,4},

4 Hong-li Dong², Zengliang Jiang^{1,5}, Jiali Wang¹, Congmei Xiao¹, Menglei Shuai¹,

5 Wanglong Gou¹, Yuanqing Fu^{1,5}, Fumiaki Imamura⁶, Yu-ming Chen^{2*}, Ju-Sheng

6 Zheng^{1,5,6*}

7

8 [#]equally contribution

9 ¹ School of Life Sciences, Westlake University, Hangzhou, China

10 ² Guangdong Provincial Key Laboratory of Food, Nutrition and Health; Department

11 of Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, China

12 ³ Department of Epidemiology and Biostatistics, School of Public Health, Zhejiang

13 Chinese Medical University, Hangzhou, China

14 ⁴ Department of Epidemiology, School of Basic Medical Sciences, Jinan University,

15 Guangzhou, China

16 ⁵ Institute of Basic Medical Sciences, Westlake Institute for Advanced Study,

17 Hangzhou, China.

18 ⁶ MRC Epidemiology Unit, University of Cambridge, Cambridge, UK

19

20

21

22

23

24 *Correspondence to

25 Prof Ju-Sheng Zheng

26 School of Life Sciences, Westlake University, 18 Shilongshan Rd, Cloud Town,

27 Hangzhou, China. Tel: +86 (0)57186915303. Email: zhengjusheng@westlake.edu.cn

28 And

29 Prof Yu-Ming Chen

30 Guangdong Provincial Key Laboratory of Food, Nutrition and Health; Department of

31 Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, China.

32 Email: chenyum@mail.sysu.edu.cn

33 Abstract

34 **Objective** To examine the association of erythrocyte n-6 polyunsaturated fatty acid
35 (PUFA) biomarkers with incident type 2 diabetes (T2D) and explore the potential role
36 of gut microbiota in the association.

37 **Design** We evaluated 2,731 non-T2D participants recruited between 2008-2013 in the
38 Guangzhou Nutrition and Health Study, China. T2D cases were identified with
39 clinical and biochemical information collected at follow-up visits. Using stool
40 samples collected during the follow-up in the subset (n=1,591), 16S rRNA profiling
41 was conducted. Using multivariable-adjusted Poisson or linear regression, we
42 examined associations of erythrocyte n-6 PUFA biomarkers with incident T2D, and
43 diversity and composition of gut microbiota.

44 **Results** Over 6.2 years of follow-up, 276 T2D cases were identified (risk=0.10).
45 Higher levels of erythrocyte γ -linolenic acid (GLA), but not linoleic or arachidonic
46 acid, were associated with higher T2D incidence. Comparing the top to the bottom
47 quartile groups of GLA levels, relative risk was 1.72 (95% confidence intervals: 1.21,
48 2.44) adjusted for potential confounders. Baseline GLA was inversely associated with
49 gut microbial richness and diversity (α -diversity, both $p<0.05$) during follow-up, and
50 significantly associated with microbiota β -diversity ($p=0.002$). Seven genera
51 (*Butyrivibrio*, *Blautia*, *Oscillospira*, *Odoribacter*, *S24-7 other*, *Rikenellaceae other*,
52 and *Clostridiales other*) were enriched in quartile 1 of GLA, and in participants
53 without T2D.

54 **Conclusion** Relative concentrations of erythrocyte GLA were positively associated

55 with incident T2D in a Chinese population and also with gut microbial profiles. These
56 results highlight that gut microbiota may play an important role linking n-6 PUFA
57 metabolism and T2D etiology.

58 INTRODUCTION

59 Type 2 diabetes (T2D) is one of the most prevalent metabolic conditions worldwide,
60 and 463 million adults are living with diabetes.¹ To examine lifestyle-related risk
61 factors for the development of T2D, the role of different fatty acids has been an
62 important research agenda. During the past two decades, consumption of n-6
63 polyunsaturated fatty acids (PUFAs), rich in vegetable oil, has been increasing
64 rapidly,^{2,3} while their relationship with human health remains controversial. The
65 metabolic pathway of n-6 PUFAs is hypothesized to be closely involved in the T2D
66 etiology,⁴ but has not been well characterized yet.

67
68 A recent pooled analysis of 20 prospective cohort studies investigated the association
69 of linoleic acid ((LA; 18:2n6) and arachidonic acid (AA; 20:4n6) biomarkers with
70 incident T2D, reporting that LA, but not AA, was inversely associated with T2D.⁵
71 However, in this pooling project, only two individual n-6 PUFA biomarkers were
72 evaluated while cohorts in Europe reported gamma-linolenic acid (GLA) and other
73 n-6 PUFAs to be associated with higher T2D risk.⁵ Moreover, with only one small
74 cohort from Taiwan in the above pooling project,⁵ evidence from Asian populations
75 has been limited. As an Asian population has different metabolic and lifestyle
76 characteristics in relation to diabetes compared to American or European
77 populations,⁶ more investigation for n-6 PUFA biomarkers in Asian populations is
78 highly warranted.

79

80 The protective effect of n-6 PUFA or LA, the most abundant n-6 PUFA, on insulin
 81 homeostasis has been well characterized and discussed to link n-6 PUFA exposure to
 82 lower T2D risk.^{7 8} However, gut microbiota has been little investigated in research on
 83 PUFAs and any non-communicable diseases. On one hand, gut microbiota has been
 84 considered as an important risk factor for T2D and insulin resistance.^{9 10} On the other,
 85 rodent studies have suggested that high tissue levels of n-6 PUFAs are associated with
 86 differences in gut microbiota, including increased *Proteobacteria*, reduced
 87 *Actinobacteria* and *Bacteroidetes*, and altered microbial α -diversity.¹¹⁻¹³ Yet, to our
 88 knowledge, there are no cohort studies investigating the potential link between n-6
 89 PUFA exposure, T2D risk, and gut microbiota composition and diversity.

90

91 Evaluating the prospective cohort in China, we aimed to examine the prospective
 92 associations 1) between n-6 PUFA biomarkers and T2D risk in a Chinese population,
 93 and 2) between n-6 PUFA biomarkers and gut microbiota composition and diversity,
 94 and subsequent health outcomes.

95

96 **METHODS**

97 **Study design and population**

98 This study was based on the Guangzhou Nutrition and Health Study (GNHS), a
 99 community-based prospective cohort in southern China. Detailed information of the
 100 participants and study design was described previously.¹⁴ Briefly, 4,048 Chinese
 101 participants aged 40-75 years and lived in Guangzhou for at least 5 years were

102 recruited between 2008-2010 (n=3,169) and 2012-2013 (n=879). All participants have
103 been followed up every 3 years approximately. During each visit, demographic,
104 dietary and lifestyle information was collected via questionnaires. The study was
105 registered at clinicaltrials.gov (NCT03179657).

106

107 According to our pre-specified inclusion and exclusion criteria of our participants for
108 the present analysis (Figure S1), we excluded participants with missing information
109 on age or sex (n=9), diet (n=7), self-reported/diagnosed T2D (n=400) or history of
110 cancer (n=16) at baseline, or extreme levels of self-reported total energy intake (<800
111 kcal or >4,000 kcal per day for men, and <500 kcal or > 3,500 kcal per day for
112 women) (n=53). We also excluded those without measurement of erythrocyte
113 membrane fatty acid compositions at baseline (n=298) and further excluded those
114 without any follow-up information on T2D status (n=534, follow-up rate 84%). The
115 current analyses were censored by date of T2D ascertainment or Apr 30, 2019, which
116 ever happened first. A total of 2,731 individuals were included in the present study,
117 with a median follow-up time of 6.2 years.

118

119 Among the above included 2,731 individuals, stool samples from 1,606 individuals
120 were collected between 2014-2018 for the subsequent 16S profiling, with 1,591
121 individuals included in the microbial association analysis after excluding participants
122 who used antibiotics within two weeks before stool collection (n=15).

123

124 **Measurement of erythrocyte membrane fatty acids and covariates**

125 We considered relative concentrations (% of total fatty acids) of erythrocyte LA, GLA,
126 and AA as the main exposure variables. Blood samples were drawn after overnight
127 fasting at the baseline visit. Erythrocytes were aliquoted within 2 hours of blood
128 sampling and stored at -80°C. As previously described,¹⁵ fatty acid moieties of
129 erythrocyte membranes were trans-methylated and measured as proportions (%) of
130 total fatty acids by using gas chromatography (7890 GC, DB-23 capillary column
131 60m×0.25mm internal diameter×0.15µm film, Agilent, California, USA).
132 Commercially available standards (Nu-Chek Prep, Minnesota, USA) were used to
133 identify individual fatty acids (n=37) and quantify a relative peak strength of each.
134 The intra-assay coefficients of variation for LA, GLA and AA were 6.4%, 12.8%, and
135 8.04%, respectively. Sociodemographic, lifestyle, and clinical covariates were
136 collected with standardized questionnaires. Details of fatty acid and covariate
137 measurements are available in Supplementary Methods.

138

139 **T2D case ascertainment**

140 At baseline (for exclusion) and follow-up visits, T2D cases were ascertained
141 according to the criteria of American Diabetes Association for T2D diagnosis¹⁶ if a
142 participant met one of the following criteria: a fasting blood glucose concentration
143 ≥ 7.0 mmol/L (126 mg/dL), or HbA1c concentration $\geq 6.5\%$, or self-reported medical
144 treatment for diabetes.

145

146 **Fecal sample collection and 16S rRNA profiling**

147 Fecal samples were collected on site during follow-up visits between 2014-2018.
 148 Microbial DNA extraction, polymerase chain reaction (PCR) and amplicon
 149 sequencing were performed as described (see Supplementary Methods). Fastq-files
 150 were demultiplexed, merge-paired, quality filtered by Quantitative Insights into
 151 Microbial Ecology software (version 1.9.0).¹⁷ Sequences were clustered into
 152 operational taxonomic units (OTUs) with 97% similarity and annotated based on the
 153 Greengenes Database (version 13.8).¹⁸

154

155 **Statistical analysis**

156 Statistical analyses were performed using Stata 15 (StataCorp, Texas, USA) or R
 157 (version 3.6.3). We used multivariable Poisson regression models to estimate the risk
 158 ratio (RR) and 95% confidence interval (CI) of T2D comparing quartiles of the
 159 erythrocyte n-6 PUFA (LA, GLA and AA), adjusting for potential confounders. We
 160 fitted three statistical models: model 1 included age, sex, BMI, and waist-hip ratio
 161 (WHR); model 2, model 1 + education, household income, smoking, alcohol drinking
 162 status, physical activity, total energy intake, and family history of diabetes; and model
 163 3, as model 2 + baseline erythrocyte total n-3 PUFAs and fasting glucose. *p*-value for
 164 trend was calculated based on per quartile difference in the corresponding n-6 PUFA
 165 variable.

166

167 In sensitivity analyses, we repeated the above analysis based on model 3 to examine

168 the impact of loss to follow up by a simple imputation (assuming that participants loss
169 to follow up did not develop T2D), and 10 rounds of multiple imputations based on
170 regression model using all covariates listed in model 3.

171

172 We assessed influences of additional potential covariates on the models: dietary
173 variables (dietary intake of dairy products, red and processed meat, fish, vegetable,
174 and fruit, in quartiles), blood lipids (total triglycerides and low-density lipoprotein),
175 prevalent coronary heart disease, treatment for hypertension or hyperlipidemia. We
176 further examined the potential interaction of erythrocyte n-6 PUFA biomarkers with
177 age, sex, BMI or n-3 PUFA biomarker concentrations on T2D risk. Post-hoc stratified
178 analyses were performed if there was a significant interaction ($p_{interaction} < 0.05$) for age,
179 sex, BMI or n-3 PUFA biomarker concentrations with the n-6 PUFA biomarkers.

180

181 For the gut microbiome analysis, we calculated the α -diversity metrics (observed
182 OTUs, Shannon's diversity index, Chao index and Simpson index) by using QIIME
183 (version 1.9.0) based on rarefied OTU counts. We standardized α -diversity indicators
184 (Z-score was calculated: the variable was subtracted by the mean and divided by the
185 standard deviation) and then reduced assay-dependent variabilities by fitting a linear
186 mixed model with an α -diversity indicator as an outcome variable and with
187 assay-specific covariates including sequencing depth and Bristol scale as fixed effects,
188 and
189 sequencing batch as a random effect. The residuals from this modeling were then used

190 in the following n-6 PUFA biomarker association analyses. We used a linear
191 regression model to examine the association of individual n-6 PUFA biomarkers (by
192 quartile) with the four α -diversity metrics, adjusted for age, sex, BMI, waist-hip ratio,
193 education, household income, smoking status, alcohol drinking status, physical
194 activity, total energy intake, and baseline erythrocyte total n-3 PUFAs. We also
195 conducted an additional adjustment for dietary fiber intake to assess the potential
196 marginal effect of dietary fiber, as fiber is a well-known factor influencing the gut
197 microbiome.¹⁹ To investigate the relevance of significant findings in relation to T2D,
198 we performed mediation analysis (R *{mediation}*)²⁰ with the residuals of α -diversity
199 as a mediator of the relationship between n-6 PUFAs and T2D, adjusting for all
200 covariates described in model 3. We examined the cross-sectional associations
201 between the residuals of α -diversity metrics and T2D by using logistic regression
202 models, adjusted for age, sex, BMI, education, household income, smoking status,
203 alcohol drinking status, prevalent hypertension and dyslipidemia.
204
205 We conducted a principal coordinate analysis (PCoA) and permutational multivariate
206 analysis of variance (PERMANOVA) (R function *adonis {vegan}*, 999
207 permutations)²¹ based on Bray-Curtis distance to compare the whole gut composition
208 (β -diversity) at genus level by quartiles of n-6 PUFA biomarkers. The potential
209 confounders included in the PERMANOVA were sequencing depth, sequencing
210 batch, Bristol scale, age, sex, BMI, WHR, education, household income, smoking
211 status, alcohol drinking status, physical activity, total energy intake, and baseline

erythrocyte total n-3 PUFAs. The above analysis was repeated for gut composition at OTU level. Scaled relative abundances (i.e., divided by the standard deviation) were used to lessen the influence of highly abundant genera on Bray-Curtis distance. The association of community structure with T2D was also assessed by PERMANOVA (R function `adonis`, 999 permutations) to obtain R^2 indicating the proportion of the variability explained by the studied variables including n-6 PUFAs. We performed the post-hoc pairwise comparisons between different quartiles of GLA with Bonferroni correction (cut-off $p < 0.008$).

At genus level, we performed a linear discrimination analysis (LDA) as implemented using LEfSe.²² The default parameters were used (α value for Wilcoxon tests was 0.05 and the LDA score was 2.0) to identify biomarkers at genus level distinguishing different quartiles of n-6 PUFAs. Only taxon present in at least 10% of samples were included in the analyses. Then, we compared the relative abundances of genera by T2D status using the LEfSe method.²² Besides, we evaluated the potential correlation of the above identified genera with T2D-related traits, including fasting insulin, glucose, total cholesterol, total triglycerides, low-density lipoprotein, high-density lipoprotein cholesterol (HDL), non-HDL, HbA1c, homeostasis model assessment of insulin resistance (HOMA-IR) and β -cell function (HOMA- β). We first modeled T2D-related traits as outcome variables in linear regression with age, sex BMI and obtained the residuals of each T2D-related trait respectively, then we calculated the Spearman correlation coefficients between the genera and the residuals of

234 T2D-related traits. Results displaying a $p < 0.05$ after Bonferroni adjustment were
235 considered as significant.

236

237 **RESULTS**

238 **Characteristics of the study participants**

239 Table 1 and Table S1 summarize the baseline characteristics of the population by
240 quartiles of erythrocyte GLA, LA and AA. The median levels (interquartile range) of
241 baseline erythrocyte LA, GLA, AA and total n-6 PUFAs (% total fatty acids) were
242 9.84 (8.89-10.76), 0.037 (0.025-0.052), 11.51 (10.00-12.60) and 21.6 (19.6-23.1),
243 respectively. Table S2 and S3 present baseline population characteristics of
244 participants with and without follow-up information, 16S profiling respectively.
245 Participants who dropped out had higher serum glucose levels, consumed fewer
246 vegetables and energy, tended to be older, less educated and physically active, and
247 were more likely to smoke.

248

249 **Association of erythrocyte n-6 PUFAs with incident T2D**

250 Higher levels of baseline GLA were associated with higher risk of T2D across the
251 three statistical models (p -trend < 0.001 for all models, Table 2). For model 3,
252 compared with the first quartile group (Q1), RRs (95% CIs) of T2D at Q2, Q3 and Q4
253 were 1.22 (0.85, 1.74), 1.43 (1.01, 2.03) and 1.72 (1.21, 2.44), respectively. No
254 association was found for LA or AA. Similar results were obtained after using the
255 simple or multiple imputation for the missing data in the sensitivity analysis (Table

S4). Adjustment for additional dietary factors and disease histories showed similar results (Table S5). We did not observe significant interaction for n-6 PUFA biomarkers with age, sex, BMI or n-3 PUFAs on T2D risk ($p_{\text{interaction}} > 0.05$).

The prospective association of erythrocyte n-6 PUFA biomarkers with gut microbiota diversity

Lower GLA was associated with higher gut microbiota α -diversity (Q4 vs. Q1: $p=0.021$ for observed OTUs, 0.028 for Shannon's diversity index, 0.023 for Chao index, respectively) (Figure 1). However, baseline LA, AA or total n-6 PUFAs were not associated with the microbial α -diversity (Table S6). These results remained similar after further adjusting for dietary fiber intake (Table S7). Among 1,591 individuals included in the microbial association analysis, we also observed positive association between GLA and T2D (Table S8). α -diversity acted as a potential partial mediator of the association between GLA and T2D (Table 3). For β -diversity, GLA and AA significantly ($p < 0.01$) contributed to dissimilarities in gut microbiota composition at genus level (Table S9). Specifically, for GLA, the gut microbiota composition at genus level was different across quartile groups of GLA concentrations (Table S10), with $p = 0.006$ for comparison between Q1 and Q4, for example, as visualized in Figure 2.

The cross-sectional association of gut microbiota diversity with T2D

T2D patients had a lower α -diversity represented by observed OTUs, Shannon's

diversity index, Simpson index and Chao index compared with patients without T2D (Table S11). We also found that the overall β -diversity was different between participants with and without T2D (Table S12).

Taxonomic profiles of gut microbial community in different levels of GLA

We then focused on exploring gut genera potentially underlying the association between GLA and incident T2D. At the genus level, the gut microbiota of participants within Q1 and Q4 of GLA was both dominated by *Bacteroides*, while the relative abundance of *Bacteroides* was significantly higher in Q4 group ($p=0.016$). We also identified *Rothia*, [*Eubacterium*], *Coprococcus* enriched in participants with high GLA levels (Q4) using LDA method (Figure 3). We found several overlapping taxonomic biomarkers for non-T2D status and low GLA status, including *Butyrivibrio*, *Blautia*, *Oscillospira*, *Odoribacter*, *S24-7 other*, *Rikenellaceae other*, and *Clostridiales other* (Figure 3). In the cross-sectional analysis relating taxonomic factors to metabolic traits, the genus [*Eubacterium*], *S24-7 other*, *Blautia*, *Oscillospira*, *Odoribacter*, *Rikenellaceae other*, *Coriobacteriaceae Other*, *Faecalibacterium* and *Christensenellaceae Other* were negatively correlated with total triglycerides (Bonferroni corrected $p<0.05$) (Figure 4). No correlation was observed for other metabolic trait-microbiota pairs (Table S13).

DISCUSSION

In the present community-based prospective cohort of a Chinese population, we found

that baseline erythrocyte GLA levels were positively associated with incident T2D, independent of BMI and other potential confounders. Proportions of LA, AA or total n-6 PUFAs were not associated with T2D incidence. Our further investigation integrating gut microbiota data revealed that GLA may be associated with T2D risk through a mechanism which varies diversity and composition of gut microbiota. Our findings suggest that n-6 PUFAs and gut microbiota co-vary in the development of T2D risk, highlighting the presence of a novel mechanism of how fatty acids or gut microbiota influence T2D risk.

Our findings suggest that high circulating GLA might be a risk factor of T2D, which are consistent with several prospective studies in western countries.^{23 24} The null finding for AA in our present study is also consistent with those from the previous studies.^{5 23 25} The findings for LA were inconsistent between ours and previous ones.⁵

²³ Circulating LA reflects habitual consumption of n-6 PUFA, typically from plant-derived oils. The inconsistency may reflect that European and Chinese populations use plant oils differently with a combination of different foods. For instance, Chinese adults may consume plant oils with meat by which positive and negative effects of those would lead to the null finding for LA. By contrast, an American or European population may use plant oils with vegetables or in a healthy diet pattern. Such dietary confounding might influence GLA finding little, as GLA is a product of tightly-regulated desaturation of LA, and result in the consistent findings between studies.

322

323 Given the putative relationship between gut microbiome and T2D, we hypothesized
324 and confirmed that gut microbiome diversity may play a role linking n-6 PUFAs and
325 T2D and that n-6 PUFAs may prospectively affect gut microbiota composition. Our
326 findings are in line with a randomized controlled trial in which α -diversity, *Blautia*
327 was reduced, while *Bacteroides* were increased after higher-fat diet intervention (rich
328 in n-6 PUFAs owing to exclusive use of soybean oil).²⁶ Although we did not observe
329 higher relative abundance of *Bacteroides* in T2D patients in our study, *Bacteroides*
330 has been found to be more abundant in T2D in another Chinese population.⁹

331

332 We found that *Butyrivibrio*, *Blautia*, *Oscillospira*, and *Odoribacter*, genera known to
333 contain a series of butyrate-producing bacteria, are all enriched in participants within
334 Q1 of GLA and participants without T2D. *Butyrivibrio fibrisolvens* was reported to
335 have the ability to utilize fructose polymers and it showed anticarcinogenic effect in
336 mice.^{27 28} *Blautia* was reported to have a lower relative abundance in T2D patients
337 and have inverse association with visceral fat.^{29 30} *Oscillospira* was positively
338 associated with leanness and was reduced in inflammatory diseases.³¹ In addition,
339 evidence suggested that some species of *Oscillospira* were able to utilize glucuronate,
340 a common animal-derived sugar.³² *Odoribacter splanchnicus* was considered as a
341 potential probiotics candidate for obesity prevention as a higher abundance in
342 obesity-depleted group.³³ Moreover, in our study, *Blautia*, *Oscillospira* and
343 *Odoribacter* were inversely associated with circulating triglycerides, which was found

344 to be positively associated with T2D and higher level of GLA.^{34 35} Thus, our study
345 suggests that lower level of GLA may be correlated with factors increasing the
346 abundance of these bacteria and preventing the development of T2D.
347
348 The more detailed mechanism behind these associations remains unclear but may be
349 related to chronic inflammation. Accumulating evidence supports the hypothesis that
350 chronic low-grade inflammation is a risk factor for the development of T2D,³⁶ and
351 that n-6 PUFA may play a vital role in the regulation of inflammation.³⁷ GLA is
352 produced from LA by the enzyme delta-6-desaturase, and is further metabolized to
353 dihomogamma-linolenic acid (DGLA; 20:3n6) which undergoes oxidative metabolism by
354 cyclooxygenases and lipoxygenases to produce anti-inflammatory eicosanoids such as
355 prostaglandins and leukotrienes.³⁸ Moreover, imbalance of the gut microbiota and
356 some specific microbes have been considered as contributors for inflammation by gut
357 microbiota-derived lipopolysaccharide(LPS)^{39 40}. The LPS stimulates Toll-like
358 receptors (TLRs) to influence innate immunity via its interaction with LPS receptors
359 (i.e., CD14/TLR 4complex).⁴¹ It can be proposed that LPS level is regulated by fat
360 and fatty acids, and associated with insulin resistance and T2D.^{40 42 43} Moreover, the
361 enrichment of inflammation-related bacteria (i.e., *Blautia*^{44 45}) in participants with
362 lower levels of GLA supports an important role of inflammation in the relationship
363 between GLA, gut microbiota and T2D.
364
365 Strengths of the present study include the prospective cohort study design, which is

366 rarely conducted in prior research on fatty acid-gut microbiota associations, and the
 367 collection and adjustment for a variety of information including socio-demographic,
 368 lifestyle and dietary factors, anthropometric parameters and circulating blood
 369 biomarkers. Several limitations merit attention. First, although we have adjusted for
 370 several potential confounders, due to the observational nature of the present study, we
 371 are not able to fully exclude the influence of residual confounding. Second,
 372 erythrocyte n-6 PUFAs were measured at baseline only and may not represent
 373 long-term status. Third, fecal samples were only collected during follow-up but not at
 374 baseline. Repeated measure of both circulating n-6 PUFAs and gut microbiota or an
 375 intervention of n-6 PUFAs would enable us to characterize bidirectional effects of n-6
 376 PUFA intakes on gut microbiota and of gut microbiota on circulating n-6 PUFAs.
 377 Nevertheless, our study fills the gap of the prospective associations between n-6
 378 PUFA biomarkers and gut microbiota.

379

380 In conclusion, our study suggests that erythrocyte GLA biomarker is positively
 381 associated with incident T2D in the Chinese population. Gut microbiota may play an
 382 important role to explain the finding. The identification of GLA-related gut
 383 microbiota features may serve as potential intervention targets for further
 384 investigation. The detailed mechanism behind the association of GLA with T2D risk
 385 and gut microbiota needs further clarification in the future.

386 **Acknowledgments** We thank all the participants and staff of the GNHS study. We
387 thank Westlake University Supercomputer Center for computational resource and
388 related assistance.

389 **Contributors** JSZ, YMC conceived the study concept and design. GDC, FFZ, HLD,
390 JW, CX collected the data. ZM, JSL, YM did the data analysis. JSZ, ZM, JSL, YM
391 wrote the first draft of the article. ZJ, MS, WG, YF, FI, YMC contributed to the
392 discussion and critical revision of the manuscript. All authors read, revised and
393 approved the final draft.

394 **Funding** This study was funded by the National Natural Science Foundation of China
395 (81903316, 81773416), Zhejiang Ten-thousand Talents Program (101396522001),
396 Westlake University (101396021801) and the 5010 Program for Clinical Researches
397 (2007032) of the Sun Yat-sen University (Guangzhou, China). The funder had no role
398 in study design, data collection and analysis, decision to publish, or writing of the
399 manuscript.

400 **Competing interests** None declared

401 **Patient consent** Obtained

402 **Ethics approval** This study was approved by the Ethics Committee of the School of
403 Public Health at Sun Yat-sen University (2018048) and Ethics Committee of Westlake
404 University (20190114ZJS0003).

REFERENCES

1. IDF. *Diabetes Atlas. 9th Edition.*; 2019. <https://diabetesatlas.org/en/>. Accessed March 18, 2020.
2. Simopoulos AP. An increase in the Omega-6/Omega-3 fatty acid ratio increases the risk for obesity. *Nutrients*. 2016;8(3). doi:10.3390/nu8030128
3. Shen X, Fang A, He J, et al. Trends in dietary fat and fatty acid intakes and related food sources among Chinese adults: A longitudinal study from the China Health and Nutrition Survey (1997-2011). *Public Health Nutr*. 2017;20(16):2927-2936. doi:10.1017/S1368980017001781
4. Patterson E, Wall R, Fitzgerald GF, Ross RP, Stanton C. Health implications of high dietary omega-6 polyunsaturated fatty acids. *J Nutr Metab*. 2012;2012. doi:10.1155/2012/539426
5. Wu JHY, Marklund M, Imamura F, et al. Omega-6 fatty acid biomarkers and incident type 2 diabetes: pooled analysis of individual-level data for 39 740 adults from 20 prospective cohort studies. *Lancet Diabetes Endocrinol*. 2017;5(12):965-974. doi:10.1016/S2213-8587(17)30307-8
6. Chan JCN, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. *JAMA - J Am Med Assoc*. 2009;301(20):2129-2140. doi:10.1001/jama.2009.726
7. Varga T, Czimmerer Z, Nagy L. PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. *Biochim Biophys Acta - Mol Basis Dis*. 2011;1812(8):1007-1022. doi:10.1016/j.bbdis.2011.02.014
8. Imamura F, Sharp SJ, Koulman A, et al. A combination of plasma phospholipid fatty acids and its association with incidence of type 2 diabetes: The EPIC-InterAct case-cohort study. *PLoS Med*. 2017;14(10). doi:10.1371/journal.pmed.1002409
9. Wang J, Qin J, Li Y, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. *Nature*. 2012;490(7418):55-60. doi:10.1038/nature11450
10. Caricilli AM, Saad MJA. The Role of Gut Microbiota on Insulin Resistance. *Nutrients*. 2013;5:829-851. doi:10.3390/nu5030829
11. Lee HC, Yu SC, Lo YC, Lin IH, Tung TH, Huang SY. A high linoleic acid diet exacerbates metabolic responses and gut microbiota dysbiosis in obese rats with diabetes mellitus. *Food Funct*. 2019;10(2):786-798. doi:10.1039/c8fo02423e
12. Kaliannan K, Li XY, Wang B, et al. Multi-omic analysis in transgenic mice implicates omega-6/omega-3 fatty acid imbalance as a risk factor for chronic disease. *Commun Biol*. 2019;2(1). doi:10.1038/s42003-019-0521-4
13. Turnbaugh PJ, Bäckhed F, Fulton L, Gordon JI. Diet-Induced Obesity Is Linked to Marked but Reversible Alterations in the Mouse Distal Gut Microbiome. *Cell Host Microbe*. 2008;3(4):213-223. doi:10.1016/j.chom.2008.02.015

14. Zhang ZQ, He LP, Liu YH, Liu J, Su YX, Chen YM. Association between dietary intake of flavonoid and bone mineral density in middle aged and elderly Chinese women and men. *Osteoporos Int*. 2014;25(10):2417-2425. doi:10.1007/s00198-014-2763-9
15. Zeng F, Sun L, Liu Y, et al. Higher Erythrocyte n-3 PUFAs Are Associated with Decreased Blood Pressure in Middle-Aged and Elderly Chinese Adults. *J Nutr*. 2014;144(8):1240-1246. doi:10.3945/jn.114.192286
16. Diagnosis and classification of diabetes mellitus. *Diabetes Care*. 2013;36(SUPPL.1). doi:10.2337/dc13-S067
17. Caporaso JG, Kuczynski J, Stombaugh J, et al. QIIME allows analysis of high-throughput community sequencing data. *Nat Methods*. 2010;7(5):335-336. doi:10.1038/nmeth.f.303
18. DeSantis TZ, Hugenholtz P, Larsen N, et al. Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. *Appl Environ Microbiol*. 2006;72(7):5069-5072. doi:10.1128/AEM.03006-05
19. Zhao L, Zhang F, Ding X, et al. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. *Science (80-)*. 2018;359(6380):1151-1156. doi:10.1126/science.aao5774
20. Tingley D, Yamamoto T, Hirose K, Keele L, Imai K. mediation: R Package for Causal Mediation Analysis. *J Stat Softw*. 2014;59(5). <http://www.jstatsoft.org/>. Accessed March 17, 2020.
21. Oksanen J, Blanchet FG, Kindt R, et al. *Package "vegan" Title Community Ecology Package.*; 2013. <http://vegan.r-forge.r-project.org/>. Accessed March 17, 2020.
22. Segata N, Izard J, Waldron L, et al. Metagenomic biomarker discovery and explanation. *Genome Biol*. 2011;12(6):R60. doi:10.1186/gb-2011-12-6-r60
23. Forouhi NG, Imamura F, Sharp SJ, et al. Association of Plasma Phospholipid n-3 and n-6 Polyunsaturated Fatty Acids with Type 2 Diabetes: The EPIC-InterAct Case-Cohort Study. *PLoS Med*. 2016;13(7). doi:10.1371/journal.pmed.1002094
24. Yary T, Voutilainen S, Tuomainen TP, Ruusunen A, Nurmi T, Virtanen JK. Serum n-6 polyunsaturated fatty acids, $\Delta 5$ - and $\Delta 6$ -desaturase activities, and risk of incident type 2 diabetes in men: The Kuopio Ischaemic Heart Disease Risk Factor Study. *Am J Clin Nutr*. 2016;103(5):1337-1343. doi:10.3945/ajcn.115.128629
25. Akter S, Kurotani K, Sato M, et al. High Serum Phospholipid Dihomo- γ -Linoleic Acid Concentration and Low $\Delta 5$ -Desaturase Activity Are Associated with Increased Risk of Type 2 Diabetes among Japanese Adults in the Hitachi Health Study. *J Nutr*. 2017;147(8):1558-1566. doi:10.3945/jn.117.248997
26. Wan Y, Wang F, Yuan J, et al. Effects of dietary fat on gut microbiota and faecal metabolites, and their relationship with cardiometabolic risk factors: a 6-month randomised controlled-feeding trial. *Gut*. 2019:gutjnl-2018-317609. doi:10.1136/gutjnl-2018-317609

- 492 27. Ohkawara S, Furuya H, Nagashima K, Asanuma N, Hino T. Oral
493 Administration of *Butyrivibrio fibrisolvens*, a Butyrate-Producing Bacterium,
494 Decreases the Formation of Aberrant Crypt Foci in the Colon and Rectum of
495 Mice. *J Nutr.* 2005;135(12):2878-2883. doi:10.1093/jn/135.12.2878
- 496 28. Cendrowska M, Kasperowicz A, Michałowski T. Preliminary assessment of the
497 capability of the rumen bacterium, *Butyrivibrio fibrisolvens*, to utilize fructose
498 polymers for growth. *J Anim Feed Sci.* 2006;15(Suppl. 1):11-14.
499 doi:10.22358/jafs/70131/2006
- 500 29. Inoue R, Ohue-Kitano R, Tsukahara T, et al. Prediction of functional profiles of
501 gut microbiota from 16S rRNA metagenomic data provides a more robust
502 evaluation of gut dysbiosis occurring in Japanese type 2 diabetic patients. *J*
503 *Clin Biochem Nutr.* 2017;61(3):217-221. doi:10.3164/jcbrn.17-44
- 504 30. Ozato N, Saito S, Yamaguchi T, et al. *Blautia* genus associated with visceral fat
505 accumulation in adults 20–76 years of age. *npj Biofilms Microbiomes.*
506 2019;5(1). doi:10.1038/s41522-019-0101-x
- 507 31. Konikoff T, Gophna U. *Oscillospira*: a Central, Enigmatic Component of the
508 Human Gut Microbiota. *Trends Microbiol.* 2016;24(7):523-524.
509 doi:10.1016/j.tim.2016.02.015
- 510 32. Gophna U, Konikoff T, Nielsen HB. *Oscillospira* and related bacteria – From
511 metagenomic species to metabolic features. *Environ Microbiol.*
512 2017;19(3):835-841. doi:10.1111/1462-2920.13658
- 513 33. Luo G, Li B, Yang C, et al. Major Traditional Probiotics: Comparative
514 Genomic Analyses and Roles in Gut Microbiome of Eight Cohorts. *Front*
515 *Microbiol.* 2019;10. doi:10.3389/fmicb.2019.00712
- 516 34. Salma MU, Nessa A, Saki SA. Relationship of HDL-C and Triglyceride with
517 Type 2 Diabetes Mellitus in Adult Female. *Mymensingh Med J.*
518 2019;28(2):306-310. <http://www.ncbi.nlm.nih.gov/pubmed/31086143>.
519 Accessed December 30, 2019.
- 520 35. Lyte JM, Gabler NK, Hollis JH. Postprandial serum endotoxin in healthy
521 humans is modulated by dietary fat in a randomized, controlled, cross-over
522 study. *Lipids Health Dis.* 2016;15(1):186. doi:10.1186/s12944-016-0357-6
- 523 36. Calle MC, Fernandez ML. Inflammation and type 2 diabetes. *Diabetes Metab.*
524 2012;38(3):183-191. doi:10.1016/j.diabet.2011.11.006
- 525 37. Ertunc ME, Hotamisligil GS. Lipid signaling and lipotoxicity in
526 metaflammation: Indications for metabolic disease pathogenesis and treatment.
527 *J Lipid Res.* 2016;57(12):2099-2114. doi:10.1194/jlr.R066514
- 528 38. Lee JM, Lee H, Kang SB, Park WJ. Fatty acid desaturases, polyunsaturated
529 fatty acid regulation, and biotechnological advances. *Nutrients.* 2016;8(1).
530 doi:10.3390/nu8010023
- 531 39. Cani PD, Osto M, Geurts L, Everard A. Involvement of gut microbiota in the
532 development of low-grade inflammation and type 2 diabetes associated with
533 obesity. *Gut Microbes.* 2012;3(4). doi:10.4161/gmic.19625
- 534 40. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity
535 and insulin resistance. *Diabetes.* 2007;56(7):1761-1772.

doi:10.2337/db06-1491

41. Bäckhed F, Normark S, Schweda EKH, Oscarson S, Richter-Dahlfors A. Structural requirements for TLR4-mediated LPS signalling: a biological role for LPS modifications. *Microbes Infect.* 2003;5(12):1057-1063. doi:10.1016/s1286-4579(03)00207-7

42. Suganami T, Tanimoto-Koyama K, Nishida J, et al. Role of the Toll-like receptor 4/NF-κB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. *Arterioscler Thromb Vasc Biol.* 2007;27(1):84-91. doi:10.1161/01.ATV.0000251608.09329.9a

43. Pendyala S, Walker JM, Holt PR. A high-fat diet is associated with endotoxemia that originates from the gut. *Gastroenterology.* 2012;142(5). doi:10.1053/j.gastro.2012.01.034

44. Jenq RR, Taur Y, Devlin SM, et al. Intestinal *Blautia* Is Associated with Reduced Death from Graft-versus-Host Disease. *Biol Blood Marrow Transplant.* 2015;21(8):1373-1383. doi:10.1016/j.bbmt.2015.04.016

45. Chen W, Liu F, Ling Z, Tong X, Xiang C. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. *PLoS One.* 2012;7(6):e39743. doi:10.1371/journal.pone.0039743

557 **Table 1. Baseline population characteristics by quartiles of erythrocyte γ -linolenic acid***
558

	γ -linolenic acid (γ C18:3n6)			
	Q1(N=682)	Q2 (N=683)	Q3 (N=683)	Q4 (N=683)
Age (year)	57.9 (6.0)	58.1 (5.8)	58.3 (5.6)	58.1 (5.2)
Sex, % of women	227 (33%)	231 (34%)	201 (29%)	167 (24%)
BMI (kg/m ²)	22.7 (3.1)	23.2 (2.9)	23.5 (3.0)	23.5 (3.1)
WHR	0.9 (0.1)	0.9 (0.1)	0.9 (0.1)	0.9 (0.1)
Education level				
Middle school or lower	176 (26%)	182 (27%)	198 (29%)	209 (31%)
High school or professional college	338 (50%)	327 (48%)	317 (46%)	303 (44%)
University	168 (25%)	174 (25%)	168 (25%)	171 (25%)
Household income (Chinese Yuan/month/person)				
≤ 500	10 (1%)	16 (2%)	13 (2%)	16 (2%)
500-1500	159 (23%)	162 (24%)	195 (29%)	188 (28%)
1500-3000	429 (63%)	407 (60%)	362 (53%)	358 (52%)
>3000	84 (12%)	98 (14%)	113 (17%)	121 (18%)
Family history of diabetes	71 (10%)	62 (9%)	76 (11%)	78 (11%)
Current smoking	110 (16%)	108 (16%)	104 (15%)	90 (13%)
Current alcohol drinking	48 (7%)	59 (9%)	32 (5%)	35 (5%)
Physical activity (MET•hours/d)	40.5 (14.0)	42.3 (15.1)	41.4 (15.3)	41.7 (15.1)
Total energy intake (kcal/d)	1759 (491)	1778 (484)	1771 (499)	1764 (471)
Dairy intake (g/d)	16.1 (13.2)	17.3 (14.5)	16.7 (15.9)	16.1 (13.6)
Red and processed meat intake (g/d)	84.5 (54.4)	84.7 (52.9)	82.4 (53.0)	84.0 (53.4)
Vegetable intake (g/d)	374.0 (189.9)	388.3 (188.0)	383.9 (260.8)	383.2 (248.2)
Fruit intake (g/d)	149.8 (107.1)	149.2 (116.6)	147.0 (112.1)	145.3 (104.6)

Dietary fiber intake (g/d)	11.2 (3.2)	11.3 (3.1)	11.4 (4.6)	11.3 (4.4)
n-3 PUFAs (%)	7.7 (1.6)	7.1 (1.6)	6.8 (1.7)	6.0 (2.0)
Fasting blood glucose (mmol/L)	4.7 (0.6)	4.7 (0.7)	4.7 (0.7)	4.7 (0.7)
Serum TG (mmol/L)	1.2 (0.9)	1.4 (0.8)	1.7 (1.1)	1.8 (1.4)
Serum HDL (mmol/L)	1.5 (0.3)	1.4 (0.3)	1.4 (0.3)	1.3 (0.3)
Serum LDL (mmol/L)	3.5 (0.8)	3.5 (0.8)	3.6 (0.9)	3.6 (1.0)

*Data are presented as mean (SD) for continuous measures, and n (%) for categorical measures. Abbreviations: BMI, body mass index; HDL, high-density lipoprotein cholesterol; IQR, interquartile range; LDL, low-density lipoprotein cholesterol; PUFAs, polyunsaturated fatty acids; Q, quartile; TG, total triglycerides; WHR, waist-to-hip ratio.

Table 2. Association of erythrocyte n-6 fatty acids with incident type 2 diabetes*

Erythrocyte n-6 fatty acids				Multivariable-adjusted RRs (95% CIs)				<i>p</i> for trend
				Q1	Q2	Q3	Q4	
Linoleic acid (C18:2n6)	Median, %			8.11	9.43	10.29	11.41	
	No. of cases/ participants		total	72/682	73/683	65/683	66/683	
	Model 1			1.00 (Ref)	0.98 (0.73, 1.33)	0.94 (0.69, 1.28)	0.97 (0.71-1.32)	0.77
	Model 2			1.00 (Ref)	1.00 (0.74, 1.35)	0.95 (0.70, 1.31)	0.98 (0.72, 1.33)	0.81
	Model 3			1.00 (Ref)	0.93 (0.69, 1.24)	0.93 (0.69, 1.26)	0.91 (0.67, 1.24)	0.59
γ -linolenic acid (γ C18:3n6)	Median, %			0.02	0.03	0.04	0.07	
	No. of cases/ participants		total	44/682	61/683	78/683	94/683	
	Model 1			1.00 (Ref)	1.33 (0.92, 1.92)	1.59 (1.12, 2.26)	1.88 (1.34, 2.64)	<0.001
	Model 2			1.00 (Ref)	1.35 (0.94, 1.95)	1.59 (1.11, 2.25)	1.85 (1.31, 2.61)	<0.001
	Model 3			1.00 (Ref)	1.22 (0.85, 1.74)	1.43 (1.01, 2.03)	1.72 (1.21, 2.44)	<0.001
Arachidonic acid (C20:4n6)	Median, %			7.73	10.90	12.02	13.41	
	No. of cases/ participants		total	77/682	75/683	68/683	56/683	
	Model 1			1.00 (Ref)	0.87 (0.64, 1.17)	0.84 (0.62, 1.14)	0.81 (0.59, 1.12)	0.19
	Model 2			1.00 (Ref)	0.86 (0.64, 1.17)	0.84 (0.62, 1.14)	0.81 (0.59, 1.12)	0.21
	Model 3			1.00 (Ref)	0.89 (0.65, 1.22)	0.96 (0.69, 1.35)	1.00 (0.71, 1.40)	0.85
Total n-6 PUFAs	Median, %			16.76	20.77	22.32	23.97	
	No. of cases/ participants		total	71/682	81/683	63/683	61/683	
	Model 1			1.00 (Ref)	1.05 (0.78, 1.41)	0.90 (0.66, 1.24)	0.97 (0.70, 1.33)	0.60

Model 2	1.00 (Ref)	1.04 (0.77, 1.41)	0.92 (0.67, 1.26)	0.96 (0.69, 1.32)	0.60
Model 3	1.00 (Ref)	1.02 (0.75, 1.39)	0.98 (0.70, 1.36)	1.05 (0.76, 1.47)	0.83

559 *Multivariable-adjusted RRs (95% CIs) were calculated for Q2-Q4 of the erythrocyte n-6 fatty acids using Q1 as the reference group. Covariates included in
560 model 1 were age, sex, BMI and waist-hip ratio; model 2, model 1 + education, household income, smoking and alcohol drinking status, physical activity,
561 total energy intake, family history of diabetes; and model 3, as model 2 + baseline erythrocyte total n-3 PUFAs and fasting glucose. *p*-value for trend was
562 calculated based on per quartile increase in the corresponding PUFA. Abbreviations: BMI, body mass index; CIs, confidence intervals; PUFAs,
563 polyunsaturated fatty acids; Q, quartile; RRs, risk ratios.

Table 3. Summary statistics of the mediation analysis for α -diversity indicators*

	n	ACME	p	ADE	p	%
Observed OTUs	1541	0.0011	0.006	0.14	0.01	7.9
Chao index	1541	0.00097	0.011	0.012	0.0093	7.1
Shannon's diversity index	1541	0.00098	0.005	0.012	0.01	7.1

* Models were built to test whether the association between γ -linolenic acid and type 2 diabetes was mediated by gut microbial α -diversity indices. The direct and indirect effect are calculated using the quasi-Bayesian Monte Carlo method with 2,000 simulations (R {*mediation*}). Covariates included age, sex, BMI and waist-hip ratio, education, household income, smoking and alcohol drinking status, physical activity, total energy intake, family history of diabetes, baseline erythrocyte total n-3 polyunsaturated fatty acids and fasting glucose. Abbreviations: BMI, body mass index.

575 **Figure legends**

576 **Figure 1 Gut microbial community richness and diversity between quartile 1 and**
 577 **quartile 4 of erythrocyte γ -linolenic acid.** The box plots feature the median (centerline),
 578 upper and lower quartiles (box limits), 1.5 \times the interquartile range (whiskers). Gut microbial
 579 community richness was represented by Observed OTUs (A) and Chao index (B), and
 580 community diversity was represented by Shannon's diversity index (C) and Simpson index
 581 (D). *p* values were calculated for Q4 (n=397) of the erythrocyte n-6 fatty acids using Q1
 582 (n=398) as the reference group using a linear mixed model: sequencing batch as
 583 random effect; sequencing depth, Bristol scale, age, sex, BMI, waist-hip ratio,
 584 education, household income, smoking and alcohol drinking status, physical activity,
 585 total energy intake, family history of diabetes, baseline erythrocyte total n-3 PUFAs
 586 and fasting glucose as fixed effects. Abbreviations: BMI, body mass index, Q,
 587 quartile.


588
 589 **Figure 2 Dissimilarities in gut microbiota composition (β -diversity) between**
 590 **quartile 1 and quartile 4 of erythrocyte γ -linolenic acid.** Dissimilarities in gut
 591 microbiota composition between quartile 1 and quartile 4 of erythrocyte γ -linolenic
 592 acid (n=795) represented by unconstrained PCoA with the Bray-Curtis dissimilarity
 593 index calculated on scaled relative abundances at genus level. Baseline erythrocyte
 594 γ -linolenic acid level explained 0.3% of the dissimilarities in gut microbiota
 595 composition (PERMANOVA, *p*= 0.002). Abbreviation: Q, quartile.

596
 597
 598 **Figure 3 Gut microbial biomarkers at genus level by γ -linolenic acid and type 2**
 599 **diabetes.** Gut microbial taxonomic biomarkers identified by the linear discriminant
 600 analysis (LDA) at quartile 1 and 4 of erythrocyte γ -linolenic acid (A), and by type 2
 601 diabetes status (B). Color indicates the group in which a differentially abundant taxon
 602 is enriched ((A) dark blue: quartile 1 of GLA; red: quartile 4 of GLA; (B) gray:
 603 participants without T2D; red: participants with T2D). Abbreviation: Q, quartile;
 604 T2D, type 2 diabetes; Non-T2D, participants without type 2 diabetes.

605


606 **Figure 4 Heatmap of the Spearman correlation coefficients between γ -linolenic**
 607 **acid-related microbes and T2D-related traits.** The intensity of the colors represents
 608 the degree of association between γ -linolenic acid-related microbes and ten
 609 T2D-related traits as measured by the Spearman's correlations. All significant
 610 correlations are marked with asterisk (Bonferroni corrected $p < 0.05$). Abbreviation:
 611 TG, total triglycerides; TC, total cholesterol; LDL, low-density lipoprotein
 612 cholesterol; HDL, high-density lipoprotein cholesterol; HOMA-IR, homeostasis
 613 model assessment of insulin resistance; HOMA- β , homeostasis model assessment of
 614 β -cell function; T2D, type 2 diabetes.

615 **Figure 1 Gut microbial community richness and diversity between quartile 1 and**
 616 **quartile 4 of erythrocyte γ -linolenic acid.**




617

618 **Figure 2 Dissimilarities in gut microbiota composition (β -diversity) between quartile 1**
 619 **and quartile 4 of erythrocyte γ -linolenic acid.**



620

621 **Figure 3 Gut microbial biomarkers at genus level by γ -linolenic acid.**



622

Figure 4 Heatmap of the Spearman correlation coefficients between γ -linolenic acid-related microbes and T2D-related traits.

